FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 19
- 试验地点
- 1
- 主要终点
- Toxicity
研究概览
简要总结
The purpose of this study is to examine the safety of a shorter course of radiation treatments combined with one year of androgen deprivation therapy. The study will test this treatment in men with high risk prostate cancer who have significant other illnesses or circumstances such that conventional long term radiotherapy and hormone therapy is not recommended by their physician or desired by the patient.
详细描述
Randomized controlled trials have established the improved efficacy (better biochemical control and disease free survival) of combined radical radiation (70-80Gy/7-8 weeks) combined with long term hormone therapy (2-3 years of adjuvant luteinizing hormone releasing hormone (LHRH) agonist) compared to a primary hormone therapy or radiotherapy alone in men with locally advanced/high risk disease. While this approach may be tolerable in fit individuals, this combination may not be well tolerated by frail individuals or those who live at a distance who may find it difficult to attend for 7 weeks of radiation due to travel considerations. Those individuals with co-morbidities such as diabetes, coronary artery disease or osteoporosis may have those conditions exacerbated by long term hormone therapy.
This pilot study will explore the combination of a stereotactic body radiotherapy (SBRT) approach (designed to be iso-effective for late effects for standard radiotherapy) combined with one year of LHRH agonist for older men with high risk disease who are less fit (Vulnerable Elderly Score > 3) or men unwilling to undertake conventionally fractionated therapy and three years of adjuvant hormone therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •High risk prostate cancer:
- •clinical stage T3 (cT3) prostate cancer or
- •pre-treatment PSA > 20 or
- •Gleason score>8 on Trans-Rectal Ultrasound (TRUS) biopsy
- •Score of > 3 on the Vulnerable Elderly Scale or refuses standard radiotherapy + androgen deprivation therapy
- •No evidence of extra-prostatic disease on screening bone scan and Computed Tomography (CT) scan (non-contrast CT used for CT simulation acceptable)
- •Signed written and voluntary informed consent provided.
- •Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
- •Age ≥ 18 years
排除标准
- •Patients not meeting the eligibility criteria
- •Prior pelvic radiotherapy or brachytherapy
- •Use of anti-coagulation (low molecular weight heparin or Coumadin)
- •History of inflammatory bowel disease, Crohn's disease, diverticulitis or collagen vascular disease (other than rheumatoid arthritis)
- •Previous treatment for malignancy (other than basal or squamous cell skin cancer) within 3 years of prostate cancer diagnosis
研究组 & 干预措施
Radiotherapy
干预措施: Stereotactic Body Radiation (Radiation)
Radiotherapy
干预措施: Luteinizing Hormone Releasing Hormone (LHRH) Agonist (Drug)
结局指标
主要结局
Toxicity
时间窗: year 3 of follow-up
Assessment of late genitourinary and gastrointestinal toxicity at year 3 as assessed by the Common Toxicity Criteria
次要结局
- Disease Free Survival(years 1, 2 and 3 of follow-up)
- Quality of Life(years 1, 2, and 3 of follow-up)
研究者
George Rodrigues
Principal Investigator
Lawson Health Research Institute